Evidence map›Paper›PMID 38239703›Full record

ArticleChemical science2024

Differential transmetallation of complexes of the anti-cancer thiosemicarbazone, Dp4e4mT: effects on anti-proliferative efficacy, redox activity, oxy-myoglobin and oxy-hemoglobin oxidation.

Mahendiran Dharmasivam, Busra Kaya, Tharushi P Wijesinghe, Vera Richardson, Jeffrey R Harmer, Miguel A Gonzalvez, William Lewis, Mahan Gholam Azad, Paul V Bernhardt, Des R Richardson

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Lysosome as a Chemical Reactor.International journal of molecular sciences · 2025
    Review
  4. Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mahendiran DharmasivamMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney Sydney New South Wales 2006 Australia.
Busra KayaCentre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University Nathan Brisbane Queensland 4111 Australia d.richardson@griffith.edu.au m.dharmasivam@griffith.edu.au.
Tharushi P WijesingheCentre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University Nathan Brisbane Queensland 4111 Australia d.richardson@griffith.edu.au m.dharmasivam@griffith.edu.au.
Vera RichardsonCentre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University Nathan Brisbane Queensland 4111 Australia d.richardson@griffith.edu.au m.dharmasivam@griffith.edu.au.
Jeffrey R HarmerCentre for Advanced Imaging, University of Queensland Brisbane Queensland 4072 Australia.
Miguel A GonzalvezSchool of Chemistry and Molecular Biosciences, University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0003-2396-8594
William LewisDepartment of Chemistry, University of Sydney New South Wales 2006 Australia.ORCID https://orcid.org/0000-0001-7103-6981
Mahan Gholam AzadCentre for Cancer Cell Biology and Drug Discovery, Griffith Institute for Drug Discovery, Griffith University Nathan Brisbane Queensland 4111 Australia d.richardson@griffith.edu.au m.dharmasivam@griffith.edu.au.
Paul V BernhardtSchool of Chemistry and Molecular Biosciences, University of Queensland Brisbane Queensland 4072 Australia.ORCID https://orcid.org/0000-0001-6839-1763
Des R RichardsonMolecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney Sydney New South Wales 2006 Australia.ORCID https://orcid.org/0000-0002-5506-3274
Griffith University · AUThe University of Queensland · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The di-2-pyridylthiosemicarbazone (DpT) analogs demonstrate potent and selective anti-proliferative activity against human tumors. The current investigation reports the synthesis and chemical and biological characterization of the Fe(iii), Co(iii), Ni(ii), Cu(ii), Zn(ii), Ga(iii), and Pd(ii) complexes of the promising second generation DpT analog, di-2-pyridylketone-4-ethyl-4-methyl-3-thiosemicarbazone (Dp4e4mT). These studies demonstrate that the Dp4e4mT Co(iii), Ni(ii), and Pd(ii) complexes display distinct biological activity

Identifiers

PMID38239703
PMCPMC10793205
OpenAlexW4389817725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.